In the last trading session, 1.8 million shares of the Denali Therapeutics Inc (NASDAQ:DNLI) were traded, and its beta was 1.52. Most recently the company’s share price was $13.27, and it changed around $0.57 or 4.49% from the last close, which brings the market valuation of the company to $1.93B. DNLI currently trades at a discount to its 52-week high of $33.33, offering almost -151.17% off that amount. The share price’s 52-week low was $10.57, which indicates that the current value has risen by an impressive 20.35% since then. We note from Denali Therapeutics Inc’s average daily trading volume that its 10-day average is 2.1 million shares, with the 3-month average coming to 1.26 million.
Denali Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.05. If we narrow it down even further, the data shows that 0 out of 20 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended DNLI as a Hold, whereas 15 deemed it a Buy, and 0 rated it as Underweight. Denali Therapeutics Inc is expected to report earnings per share of -0.71 for the current quarter.
Denali Therapeutics Inc (NASDAQ:DNLI) trade information
Instantly DNLI has showed a green trend with a performance of 4.49% at the end of last trading. The performance over the last five days has remained in the green territory. The rise to weekly highs of 13.36 on recent trading dayincreased the stock’s daily price by 0.67%. The company’s shares are currently down -34.89% year-to-date, but still up 14.40% over the last five days. On the other hand, Denali Therapeutics Inc (NASDAQ:DNLI) is -12.41% down in the 30-day period. We can see from the shorts that 11.44 million shares have been sold at a short interest cover period of 7.98 day(s).
The consensus price target as assigned by Wall Street analysts is $38.5, which translates to bulls needing to increase their stock price by 65.53% from its current value. Analyst projections state that DNLI is forecast to be at a low of $32 and a high of $45.
Consensus estimates provided by 11 financial analysts predict the company will bring in an average of 3.24M in revenue for the current quarter. 11 analysts expect Denali Therapeutics Inc to make 7.79M in revenue for the current ending quarter. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -4.46%. Denali Therapeutics Inc earnings are expected to increase by -13.20% in 2025, but the outlook is positive 9.16% per year for the next five years.
DNLI Dividends
Denali Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Feb-26.
Denali Therapeutics Inc (NASDAQ:DNLI)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 9.56% of Denali Therapeutics Inc shares, and 90.84% of them are in the hands of institutional investors. The stock currently has a share float of 100.45%. Denali Therapeutics Inc stock is held by 334.0 institutions, with BAILLIE GIFFORD & CO being the largest institutional investor. By 2024-06-30, it held 8.1523% of the shares, which is about 13.76 million shares worth $319.59 million.
BLACKROCK INC., with 7.8034% or 13.17 million shares worth $305.91 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and SMALLCAP WORLD FUND INC were the top two Mutual Funds as of Jan 31, 2025 . The former held 7.97 shares worth $105.78 million, making up 5.49% of all outstanding shares. On the other hand, SMALLCAP WORLD FUND INC held roughly 3.81 shares worth around $50.53 million, which represents about 2.62% of the total shares outstanding.
